Literature DB >> 27245283

Immunotherapy: Response to nivolumab in RCC: RECISTing progression.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27245283     DOI： 10.1038/nrclinonc.2016.93

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

Authors:  Saby George; Robert J Motzer; Hans J Hammers; Bruce G Redman; Timothy M Kuzel; Scott S Tykodi; Elizabeth R Plimack; Joel Jiang; Ian M Waxman; Brian I Rini
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.